CClinicalTrials.gg
Status unknownNCT01744743Updated Dec 11, 2012

Preconceptional Thyroid Screening and Childhood Nerocognitive Function

An interventional study of levothyroxine in Hypothyroidism, sponsored by Fudan University. Status unknown at 1 site in China. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-12-11.

Sponsored by Fudan University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

To assess the effect of universal preconception hypothyroidism for maternal pregnancy outcome, and 0-3yrs offspring neurocognitive ability and IQ score.

Read the detailed description

Epidemic evidence and animal studies suggested that hypothyroidism is related with maternal pregnancy outcome, offspring cognitive ability. Negro's study found improved maternal health in those screened in early trimester; while Lazarus et al. reported no significant offspring IQ score at 3yrs in universal screening in early trimester. Currently, it lacks evidence of universal pre-conception screening for maternal pregnancy outcome and offspring cognitive development, motivation ability, attention. China Governmental Health Department has included thyroid function screening into preconception in 2011. The investigators hypothesize that pre-conception effective treatment may be helpful for decrease possible negative effects on maternal and offspring health, instead of early trimester.

02

Conditions studied

  • Hypothyroidism

Browse trials for

Keywords

  • preconception
  • hypothyroidism
  • neurocognitive development
03

In context

Hypothyroidism

247 studies on the registry are indexed under Hypothyroidism; 57 are open to participants now.

This study's planned enrollment of 600 is above the median of 78 across 128 interventional studies indexed under Hypothyroidism.

Browse Hypothyroidism studies →

Lead sponsor

Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Preconceptional group:TSH ≥ 97.5%th and/or FT4 ≤ 2.5%th
  2. age: 18-55
  3. those who can obey the rules of this study and assign the consent

Exclusion criteria

Exclusion Criteria:

  1. age: less than 18 or more than 55
  2. multiple pregnancy
  3. thyroid tumor disease history
  4. those who cannot obey the rules of this study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    preconception

    Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old

    Procedure: levothyroxine

  • Active comparator
    early conception

    Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old

    Procedure: levothyroxine

  • Placebo comparator
    late conception

    Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old

    Procedure: levothyroxine

Interventions

  • Procedurelevothyroxine

    Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Offspring neurocognitive assessment at 0-3 yrs

    Peabody scale, Griffith scale

    Time frame: 3 months, 6 months, 1 year, 2 years, 3 years

  2. Offspring IQ assessment at 0-3 yrs

    Wechsler Preschool Intelligence Scale at 1, 2, 3-year-old

    Time frame: 3 months, 6 months, 1 year, 2 years, 3 years

Secondary outcomes

  1. Incidence of neonatal hypothyroid and complications

    neonatal hypothyroid function, NICU rate, neonatal death rate

    Time frame: up to 28 days of birth

Other outcomes

  1. Incidence of maternal complications

    preeclampsia, GDM, maternal death rate, maternal hemorrhage rate

    Time frame: up to 42 days postpartumn

07

Study locations

1 of 1 sites recruiting
  • Obstetrics and Gynecology Hospital, Fudan University
    Shanghai, Shanghai 200011, China
    Recruiting
08

References and documents

Publications

  • Zhou Q, Wang C, Xu H, Li X. Impact of Preconception Treatment Initiation for Hypothyroidism on Neurocognitive Function in Children. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa565. doi: 10.1210/clinem/dgaa565. PubMed 32841335 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01744743
Lead sponsor
Fudan University
Collaborators
Shanghai Municipal Science and Technology Commission, Shanghai Municipal Health Bureau
Responsible party
Xiaotian Li (Vice president, Cheif of Obstetrics Department, Obstetrics and Gynecology Hospital, Fudan University) — Principal investigator
First posted
Dec 7, 2012
Start date
Jan 2011
Primary completion
Dec 2014 (estimated)
Completion
Dec 2015 (estimated)
Last update
Dec 11, 2012

Study contacts

Xiaotian Li, MD, PhD
Contact
xiaotianli555@163.com
862163455050
Qiongjie Zhou, MD
Contact
qj_zhou@163.com
862163455050
Xiaotian Li, MD, PhD
principal investigator · Obstetrics and Gynecology Hospital, Fudan University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion